Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders
Autumn Walkerly,Lauren D Leader,Emily Cooke,Amy VandenBerg
DOI: https://doi.org/10.2147/DDDT.S240856
2021-07-09
Abstract:Autumn Walkery, 1 Lauren D Leader, 1 Emily Cooke, 2 Amy VandenBerg 1 1 Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA; 2 Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA Correspondence: Lauren D Leader Michigan Medicine, Department of Pharmacy Services, 1540 E. Medical Center Dr., Ann Arbor, MI, 48109 Tel +1 734 647-5938 Email Objective: This paper reviews the current literature available for the efficacy and safety of allopregnanolone agonists and discusses considerations for their place in therapy. Literature Search: A literature search was conducted utilizing PubMed, clinicaltrials.gov, and the manufacturer's website. Data Synthesis: One phase II trial and two phase III trials evaluating the efficacy and safety of brexanolone were identified. Brexanolone demonstrated efficacy through significantly reduced Hamilton Depression Rating Scale (HAM-D) scores compared to placebo in the treatment of postpartum depression (PPD). Noted adverse effects were somnolence and dizziness, excessive sedation, and loss of consciousness. One published phase II study and the interim results of two phase III trials and one phase II trial on zuranolone were included in this review. Zuranolone, an oral allopregnanolone agonist, is given as a single, 14-day course. A significant reduction in HAM-D scores was demonstrated in patients with major depressive disorder (MDD) at 15 and 28 days compared to placebo. Interim results for zuranolone in PPD and bipolar disorder (BPD) show promising reductions in HAM-D scores. Adverse effects included sedation, dizziness, and headache. Place in Therapy: Allopregnanolone agonists seem to have a role in PPD when weighing the quick onset of action and potential risks of untreated PPD. The class of medications is limited by the single course for this indication and may fit as a bridge to maintenance therapy with selective serotonin reuptake inhibitors (SSRIs). Brexanolone, specifically, is hindered by the long infusion time, hospitalization associated with administration, and risk evaluation and mitigation strategy program. Zuranolone may also have a role in MDD or BPD, but more data are needed. Conclusion: Allopregnanolone agonists present a novel mechanism of action in the treatment of depressive disorders. Clinical trials and interim results support significant reductions in depression scores for brexanolone in PPD, and for zuranolone in PPD, MDD, and BPD. Keywords: postpartum, bipolar, brexanolone, zuranolone Mental illnesses are highly prevalent in the United States (USA), with approximately 51.5 million (20%) of US adults indicating a mental illness in a 2019 survey. 1 Major depressive disorder (MDD) affected nearly 17.3 million adults in the USA as of 2017, and between 2001 and 2003 there were 2.8% of US adults diagnosed with bipolar disorder (BPD). 2 , 3 Effective treatment of depressive disorders is imperative as the cost is high. Approximately 15% of people with MDD will attempt and/or think about dying by suicide. 4 Currently available therapies for the treatment of depression and adjunctive treatment of BPD primarily target modulation of the neurotransmitters serotonin and norepinephrine. These therapies are limited by delayed onset (4–6 weeks), lack of acute improvement in suicidality, and risk of mania when used to treat bipolar depression. 5 , 6 Increasing evidence supports the idea that neuroactive steroids, specifically allopregnanolone, represent a novel target for the treatment of depression. 7 In the presence of acute stress, allopregnanolone concentrations increase significantly. 7 The increase in allopregnanolone is hypothesized to be neuroprotective. However, under chronic stress and in MDD, decreases in allopregnanolone concentrations in the central nervous system have been demonstrated, resulting in altered gamma-aminobutyric acid (GABA) and glutamate transmission. 8 Allopregnanolone is thought to improve depressive symptoms through modulation of the GABA A pathway and regulation of the hypothalamic–pituitary–adrenocortical (HPA) axis, which facilitates recovery of physiological homeostasis. 9 Allopregnanolone agonists are being developed as a potential treatment option for mental health disorders, exploiting the GABA A pathway activated by neuroactive steroids. For decades, GABA A receptors have been considered to have a role -Abstract Truncated-